Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
06:32
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

52nd ERA-EDTA Congress

 

28-31 May 2015 London
FAQs
   
Discussion forum - 52nd ERA-EDTA Congress
    Topic - L5) Dialysis. Anaemia.

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
PHARMACOKINETICS AND PHARMACODYNAMICS OF LEXAPTEPID, A NOVEL ANTI-HEPCIDIN MOLECULE, IN ESA-RESISTANT HAEMODIALYSIS PATIENTS  Iain C. Macdougall 1      5/30/2015 11:22:00 AM  
IMPACT OF EUROPEAN MEDICINES AGENCY RECOMMENDATIONS FOR ALLERGIC REACTIONS TO INTRAVENOUS IRON-CONTAINING DRUGS IN DIALYSIS CENTERS OF LOMBARDY REGION  Rodolfo Rivera 1      5/18/2015 11:12:00 PM  
INFLUENCE OF THE SECONDARY HYPERPARATHYROIDISM IN IRON REQUIREMENTS IN DIALYSIS PATIENTS ON ERYTHROPOIESIS-STIMULATING AGENT THERAPY. A PROSPECTIVE CONTROLLED STUDY.  Sheila Cabello Pelegrín 1      5/18/2015 10:05:00 PM  
EFFECTS OF ASCORBIC ACID ADMNISTRATION ON ANAEMIA CORRECTION IN HEAMODIALYSIS PATIENTS  Grnea355;259; Liliana 1      5/18/2015 9:21:00 PM  
EXPLORING THE ASSOCIATION BETWEEN FERRITIN LEVELS AND MORTALITY IN THE UK HAEMODIALYSIS POPULATION.  Anirudh Rao 1      5/18/2015 8:15:00 PM  
HEMODIALYSIS PATIENTS WITH PRE-DIALYSIS SODIUM BELOW 140 MMOL/L HAVE SIGNIFICANTLY HIGHER LEVELS OF ERYPTOSIS  Viktoriya Kuntsevich 1      5/18/2015 5:28:00 PM  
THE SEQUENTIAL CHANGE OF SERUM HEPCIDIN-25(HPC) LEVEL AND OTHER IRON METABOLISM MARKERS AFTER SINGLE INTRAVENOUS IRON ADMINISTRATION IN HEMODIALYSIS(HD) PATIENTS.  Noriko Saito 1      5/18/2015 1:21:00 PM  
POST-DIALYSIS HEMOGLOBIN IS ASSOCIATED WITH ONE YEAR MORTALITY IN HEMODIALYSIS PATIENTS. RESULT FROM A COHORT STUDY FROM THE DIALYSIS REGISTRY IN JAPAN.  Hiroki Nishiwaki 1      5/17/2015 2:15:00 PM  
VITAMIN D DEFICIENCY IS AN INDEPENDENT RISK FACTOR FOR ANEMIA IN PATIENTS WITH END-STAGE RENAL DISEASE  In Mee Han 1      5/15/2015 12:09:00 PM  
JTZ-951, A NOVEL HIF-PHD INHIBITOR, DEMONSTRATES INCREASES IN HEMOGLOBIN, IRON MOBILIZATION, REPRODUCIBLE PHARMACOKINETICS, AND SAFETY FOLLOWING ONCE DAILY ADMINISTRATION FOR 15 DAYS IN PATIENTS WITH ANEMIA RECEIVING HEMODIALYSIS  Sudhakar Pai 1      5/14/2015 7:38:00 PM  
LOW LEVELS OF SERUM FERRITIN WITH MODERATE LEVEL OF TRANSFERRIN SATURATION MAINTAINS ADEQUATE HEMOGLOBIN IN HEMODIALYSIS PATIENTS  Chie Ogawa 1      5/12/2015 8:01:00 AM  
METHOD TO CALCULATE ESA DOSE TO ACHIEVE TARGET HAEMOGLOBIN LEVEL BY ANALYSING HAEMOGLOBIN KINETIC MODEL  Tadashi Kuji 1      5/12/2015 6:13:00 AM  
CONTINUOUS ERYTHROPOIESIS ACTIVATOR HAS A FAVORABLE EFFECTS FOR IRON UTILIZATION AMONG PERITONEAL DILAYSIS PATINTS WITHOUT ABSOLUTE IRON DEFICIENCY.  Takeshi Hasegawa 1      5/9/2015 11:46:00 AM  
FECAL CALPROTECTIN AND HB VARIABILTY : AN INTRIGUING ASPECT  Luciano De paola 1      5/5/2015 4:20:00 PM  
FAVORABLE EFFECT OF PARICALCITOL ON ERYTHROPOIESIS IN PATIENTS UNDERGOING CHRONIC HEMODIALYSIS TREATMENT  Christos Paliouras 1      5/4/2015 6:40:00 PM  
INTRAVENOUS IRON ADMINISTRATION AND EARLY ATHEROGESESIS, IS ACTUALLY IRON SUCROSE RESPONSIBLE ?  Jorge Toblli 1      5/3/2015 6:17:00 AM  
INTRAVENOUS IRON THERAPY CAN BE A SECOND CHOICE OF TREATMENT IN HEMODIALYSIS PATIENTS WITH IRON DEFICIENCY ANAEMIA WHO FAIL TO MAINTAIN THE TARGET HEMOGLOBIN AFTER ORAL IRON THERAPY  Kazuya Takasawa 1      4/17/2015 4:41:00 PM  
       




Most viewed poster for this congress
Poster: 625
Visits: 3858
Title: IS 4 CITRATE AN EFFECTIVE TOOL AS A CATHETER LOCKING SOLUTION?
Authors: Joao Fazendeiro Matos ,
Centre: Fresenius Medical Care | NephroCare Portugal

Poster most viewed in this topic
Poster: 658
Visits: 209
Title: JTZ-951, A NOVEL HIF-PHD INHIBITOR, DEMONSTRATES INCREASES IN HEMOGLOBIN, IRON MOBILIZATION, REPRODUCIBLE PHARMACOKINETICS, AND SAFETY FOLLOWING ONCE DAILY ADMINISTRATION FOR 15 DAYS IN PATIENTS WITH ANEMIA RECEIVING HEMODIALYSIS
Authors: Sudhakar Pai , R. Koretomo, S. Tamaki, J. Berg, T. Marbury, C. Galloway, R. Preston
Centre: Akros Pharma, Inc.


 






PosterSessionOnline
Logo Draft
 
Logo Cert